Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Open in API
Filings indexed 208 across all filing types
Latest filing 2023-12-20 Capital/Financing Update
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of the final tranche of a $4.5 million non-brokered private placement by Thiogenesis Therapeutics. It details the issuance of common shares, finder's fees, and the use of proceeds from the offering. There is no financial statement or detailed financial report included, only an update on financing activity. The document is about fundraising and capital structure changes, which fits the Capital/Financing Update category. The document length is 6271 characters, which is sufficient for a detailed announcement but does not contain financial statements or analysis that would classify it as an Interim Report or Annual Report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-12-20 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a non-brokered private placement of common shares by Thiogenesis Therapeutics, including details about the number of shares issued, gross proceeds, finder's fees, insider participation, and intended use of proceeds. It discusses financing activities and capital raising but does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or regulatory filing of financial results. The content fits the definition of a Capital/Financing Update, as it provides an update on the company's fundraising and capital structure changes.
2023-12-18 English
News release - English.pdf
Regulatory Filings
2023-12-06 English
News release - English.pdf
Regulatory Filings
2023-11-27 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a non-brokered private placement of common shares by Thiogenesis Therapeutics Corp. It details the offering size, share price, use of proceeds, and regulatory approvals required. It also provides corporate updates and clinical trial milestones but does not contain any financial statements or detailed financial performance data. The primary focus is on fundraising and capital raising activities. There is no indication that this is a full financial report, audit, or earnings release. The document is not a report publication announcement since it contains substantive information about the financing and corporate updates rather than just announcing a report's availability. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-11-20 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form titled 'FORM 52-109FV2' which is a 'Certification of Interim Filings' for a venture issuer. It is signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2023. The document explicitly states it is a certificate and does not contain the actual interim financial data or analysis but rather attests to the accuracy and completeness of such filings. According to the Certification Rule, documents that are primarily officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS) rather than the interim report itself. The document length is short (3055 characters) and it is a certification, not the report itself.
2023-11-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.